



October 18, 2017

Company name: Mitsubishi Tanabe Pharma Corporation  
Representative: Masayuki Mitsuka  
President and Representative Director  
Code number: 4508, First Section, Tokyo Stock Exchange  
Contact: Yoshifumi Mifune, General Manager,  
Corporate Communications Department  
TEL: +81-6-6205-5211

### **Completion of Acquisition of NeuroDerm (100% Ownership)**

With regard to the announcement “Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.,” which was released on July 24, 2017, Mitsubishi Tanabe Pharma Corporation (“MTPC”) hereby reports that the procedures for MTPC’s acquisition of NeuroDerm Ltd. (Nasdaq: NDRM) (“NeuroDerm”) have been completed on October 18, 2017 (IDT: Israel Daylight Time).

The acquisition was conducted through a reverse triangular merger, in which MTPC’s wholly-owned merger subsidiary established in Israel solely for the purpose of the acquisition process merged into NeuroDerm, with NeuroDerm surviving the merger. Pursuant to the merger, MTPC acquired all of the outstanding shares (including shares underlying options) of NeuroDerm at a total equity value of US\$1.1 billion (US\$39.00 per share), paid in cash. As a result of the acquisition, NeuroDerm has become a wholly-owned subsidiary of MTPC, and its shares will cease to be traded on Nasdaq as of October 18, 2017.

MTPC is currently examining the potential impact of the acquisition on MTPC’s consolidated business results. Additional guidance will be presented as soon as the impact is determined.

End